Search Results - "Jin Kang, Hyoung"

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study by Goss, Glenwood, Dr Prof, Tsai, Chun-Ming, Prof, Shepherd, Frances A, Prof, Bazhenova, Lyudmila, Prof, Lee, Jong Seok, MD, Chang, Gee-Chen, MD, Crino, Lucio, MD, Satouchi, Miyako, MD, Chu, Quincy, MD, Hida, Toyoaki, MD, Han, Ji-Youn, Prof, Juan, Oscar, MD, Dunphy, Frank, Prof, Nishio, Makoto, MD, Kang, Jin-Hyoung, MD, Majem, Margarita, MD, Mann, Helen, MSc, Cantarini, Mireille, MD, Ghiorghiu, Serban, MD, Mitsudomi, Tetsuya, Prof

“…Summary Background Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor…”
Get full text

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial by Nakagawa, Kazuhiko, Garon, Edward B, Seto, Takashi, Chiu, Chao-Hua, Novello, Silvia, Nadal, Ernest, Imamura, Fumio, Au, Kwok Hung, Moro-Sibilot, Denis, Enatsu, Sotaro, Zimmermann, Annamaria, Frimodt-Moller, Bente, Visseren-Grul, Carla, Reck, Martin, Chu, Quincy, Pujol, Jean-Louis, Moro-Sibilot, Denis, Lamour, Corinne, Bischoff, Helge, Kollmeier, Jens, Reck, Martin, Kimmich, Martin, Hammerschmidt, Stefan, Schütte, Wolfgang, Syrigos, Konstantinos, Ho, James Chung Man, Au, Kwok-Hung, Novello, Silvia, Ardizzoni, Andrea, Pasello, Giulia, Gregorc, Vanessa, Del Conte, Alessandro, Galetta, Domenico, Takahashi, Toshiaki, Nakagawa, Kazuhiko, Nishio, Makoto, Yoh, Kiyotaka, Seto, Takashi, Imamura, Fumio, Kumagai, Toru, Hotta, Katsuyuki, Goto, Yasushi, Hosomi, Yukio, Sakai, Hiroshi, Kim, Young Hak, Kurata, Takayasu, Daga, Haruko, Okamoto, Isamu, Satouchi, Miyako, Ikeda, Satoshi, Atagi, Shinji, Azuma, Koichi, Horio, Yoshitsugu, Tanaka, Hiroshi, Watanabe, Satoshi, Nogami, Naoyuki, Ozaki, Tomohiro, Koyama, Ryo, Kaneda, Hiroyasu, Tomii, Keisuke, Seike, Masahiro, Nishimura, Naoki, Kato, Terufumi, Saka, Hideo, Hirano, Katsuya, Nakahara, Yasuharu, Sugawara, Shunichi, Kim, Sang-We, Min, Young Joo, Kang, Jin-Hyoung, An, Ho Jung, Lee, Ki Hyeong, Kim, Jin-Soo, Lee, Gyeong-Won, Lee, Sung Yong, Udrea, Anghel Adrian, Juan-Vidal, Óscar, Nadal-Alforja, Ernest, Gil-Bazo, Ignacio, Ponce-Aix, Santiago, Paz-Ares, Luis, Rubio-Viqueira, Belén, Alonso Garcia, Miriam, Felip Font, Enriqueta, Fuentes Pradera, Jose, Lin, Meng-Chih, Su, Wu-Chou, Chang, Gee-Chen, Wei, Yu-Feng, Chiu, Chao-Hua, Cicin, Irfan, Goksel, Tuncay, Harputluoglu, Hakan, Ozyilkan, Ozgur, Henning, Ivo, Popat, Sanjay, Hatcher, Olivia, Acoba, Jared, Garon, Edward, Jung, Gabriel

“…Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet…”
Get full text

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing by Ju, Young Seok, Lee, Won-Chul, Shin, Jong-Yeon, Lee, Seungbok, Bleazard, Thomas, Won, Jae-Kyung, Kim, Young Tae, Kim, Jong-Il, Kang, Jin-Hyoung, Seo, Jeong-Sun

“…The identification of the molecular events that drive cancer transformation is essential to the development of targeted agents that improve the clinical…”
Get full text

The transcriptional landscape and mutational profile of lung adenocarcinoma by Seo, Jeong-Sun, Ju, Young Seok, Lee, Won-Chul, Shin, Jong-Yeon, Lee, June Koo, Bleazard, Thomas, Lee, Junho, Jung, Yoo Jin, Kim, Jung-Oh, Shin, Jung-Young, Yu, Saet-Byeol, Kim, Jihye, Lee, Eung-Ryoung, Kang, Chang-Hyun, Park, In-Kyu, Rhee, Hwanseok, Lee, Se-Hoon, Kim, Jong-Il, Kang, Jin-Hyoung, Kim, Young Tae

“…All cancers harbor molecular alterations in their genomes. The transcriptional consequences of these somatic mutations have not yet been comprehensively…”
Get full text

Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study by Park, Keunchil, Jӓnne, Pasi A., Kim, Dong‐Wan, Han, Ji‐Youn, Wu, Ming‐Fang, Lee, Jong‐Seok, Kang, Jin‐Hyoung, Lee, Dae Ho, Cho, Byoung Chul, Yu, Chong‐Jen, Pang, Yong Kek, Felip, Enriqueta, Kim, Hyunjin, Baek, Eunhye, Noh, Young Su

“…Background In this open‐label, international phase 2 study, the authors assessed the efficacy and safety of olmutinib in patients with locally advanced or…”
Get full text

Two‐year follow‐up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141) by Yen, Chia‐Jui, Kiyota, Naomi, Hanai, Nobuhiro, Takahashi, Shunji, Yokota, Tomoya, Iwae, Shigemichi, Shimizu, Yasushi, Hong, Ruey‐Long, Goto, Masahiro, Kang, Jin‐Hyoung, Li, Wing Sum Kenneth, Ferris, Robert L., Gillison, Maura, Endo, Toshimitsu, Jayaprakash, Vijayvel, Tahara, Makoto

“…Background The present study evaluated the 2‐year survival of the Asian population in the CheckMate 141 trial. Methods The CheckMate 141 trial included…”
Get full text

A randomised phase 2b study comparing the efficacy and safety of belotecan vs. topotecan as monotherapy for sensitive-relapsed small-cell lung cancer by Kang, Jin-Hyoung, Lee, Ki-Hyeong, Kim, Dong-Wan, Kim, Sang-We, Kim, Hye Ryun, Kim, Joo-Hang, Choi, Jin-Hyuk, An, Ho Jung, Kim, Jin-Soo, Jang, Joung-Soon, Kim, Bong-Seog, Kim, Heung Tae

“…Background This study compared the efficacy/safety of the camptothecin analogues belotecan and topotecan for sensitive-relapsed small-cell lung cancer (SCLC)…”
Get full text

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy by Lee, Dae Ho, Park, Keunchil, Kim, Joo Hang, Lee, Jong-Seok, Shin, Sang Won, Kang, Jin-Hyoung, Ahn, Myung-Ju, Ahn, Jin Seok, Suh, Cheolwon, Kim, Sang-We

“…Purpose: The ISTANA (IRESSA as Second-line Therapy in Advanced NSCLC—KoreA) study compared gefitinib with docetaxel in patients with advanced or metastatic…”
Get full text

Should We Consider Value Frameworks for Cancer Drugs as Oncology's Landscape Evolves?; from an Oncologist Perspective in Korea by Kim, Do Yeun, Ha, Hyerim, Bae, SeungJin, Kang, Jin-Hyoung

“…BACKGROUNDAs the role of immunotherapies and personalized medicine grow, cancer patients have faced many choices in treatments and have suffered financial…”
Get full text

First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO‐4538‐52/TASUKI‐52 randomized controlled trial by Kim, Hye Ryun, Sugawara, Shunichi, Lee, Jong‐Seok, Kang, Jin‐Hyoung, Inui, Naoki, Hida, Toyoaki, Lee, Ki Hyeong, Yoshida, Tatsuya, Tanaka, Hiroshi, Yang, Cheng‐Ta, Nishio, Makoto, Ohe, Yuichiro, Tamura, Tomohide, Yamamoto, Nobuyuki, Yu, Chong‐Jen, Akamatsu, Hiroaki, Takahashi, Shigeru, Nakagawa, Kazuhiko

“…Background ONO‐4538‐52/TASUKI‐52 was performed in Japan, Korea, and Taiwan to determine the oncological effectiveness and safety of combining nivolumab or…”
Get full text

Fractionated Stereotactic Radiotherapy as Reirradiation for Locally Recurrent Head and Neck Cancer by Roh, Kwang-Won, M.D, Jang, Ji-Sun, Ph.D, Kim, Min-Sik, M.D, Sun, Dong-IL, M.D, Kim, Bum-Soo, M.D, Jung, So-Lyoung, M.D, Kang, Jin-Hyoung, M.D, Yoo, Eun-Jung, M.D, Yoon, Sei-Chul, M.D, Jang, Hong-Seok, M.D, Chung, Su-Mi, M.D, Kim, Yeon-Sil, M.D

“…Purpose We report early preliminary experience with CyberKnife radiosurgery (RS) as salvage treatment for locally recurrent head and neck cancer (HNC). Methods…”
Get full text

Anti-tumor efficacy of CKD-516 in combination with radiation in xenograft mouse model of lung squamous cell carcinoma by Kim, Min-Young, Shin, Jung-Young, Kim, Jeong-Oh, Son, Kyoung-Hwa, Kim, Yeon Sil, Jung, Chan Kwon, Kang, Jin-Hyoung

“…Hypoxic tumors are known to be highly resistant to radiotherapy and cause poor prognosis in non-small cell lung cancer (NSCLC) patients. CKD-516, a novel…”
Get full text

Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations by Murakami, Haruyasu, Nokihara, Hiroshi, Hayashi, Hidetoshi, Seto, Takashi, Park, Keunchil, Azuma, Koichi, Tsai, Chun‐Ming, Yang, James Chih‐Hsin, Nishio, Makoto, Kim, Sang‐We, Kiura, Katsuyuki, Inoue, Akira, Takeda, Koji, Kang, Jin‐Hyoung, Nakagawa, Tomoki, Takeda, Kentaro, Akazawa, Rio, Kaneko, Yuichiro, Shimazaki, Masashi, Morita, Satoshi, Fukuoka, Masahiro, Nakagawa, Kazuhiko

“…Epidermal growth factor receptor (EGFR)‐activating mutations confer sensitivity to tyrosine kinase inhibitor (TKI) treatment for non‐small‐cell lung cancer…”
Get full text

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations by Park, Keunchil, Kim, Jin-Soo, Kim, Joo-Hang, Kim, Young-Chul, Kim, Hoon-Gu, Cho, Eun Kyung, Jin, Jong-Youl, Kim, Miyoung, Märten, Angela, Kang, Jin-Hyoung

“…Afatinib is approved globally for EGFR-TKI treatment-naïve patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). In this Korean expanded…”
Get full text

LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells by Shin, Jung-Young, Kim, Jeong-Oh, Lee, Suk Kyeong, Chae, Hiun-Suk, Kang, Jin-Hyoung

“…As EBV-associated gastric cancer has unique features that are different from EBV (-) gastric cancer, EBV is considered to have a key role in gastric…”
Get full text

Patient and oncologist perceptions regarding symptoms and impact on quality-of-life of oral mucositis in cancer treatment: results from the Awareness Drives Oral Mucositis PercepTion (ADOPT) study by Kanagalingam, Jeevendra, Wahid, Mohamed Ibrahim A., Lin, Jin-Ching, Cupino, Nonette A., Liu, Edward, Kang, Jin-Hyoung, Bazarbashi, Shouki, Bender Moreira, Nicole, Arumugam, Harsha, Mueller, Stefan, Moon, Hanlim

“…Purpose This descriptive cross-sectional survey aims to assess the level of concordance between the perspectives of oncologists and those of patients regarding…”
Get full text

Prognostic value of 18F‐FDG PET parameters in patients with locally advanced non‐small cell lung cancer treated with induction chemotherapy by Lee, Hee Yeon, Choi, Woo Hee, Yoo, Ie Ryung, Park, Jae Kil, Sung, Sook Whan, Kim, Yeon Sil, Kang, Jin‐Hyoung

“…Aim To investigate predictive and prognostic role of metabolic parameters using [18F]‐2‐fluoro‐2‐deoxy‐D‐glucose positron emission tomography (18F‐FDG PET) in…”
Get full text

Expression of Viral MicroRNAs in Epstein-Barr Virus-Associated Gastric Carcinoma by DO NYUN KIRN, CHAE, Hiun-Suk, SANG TAEK OH, KANG, Jin-Hyoung, CHO HYUN PARK, WON SANG PARK, TAKADA, Kenzo, JAE MYUN LEE, LEE, Won-Keun, SUK KYEONG LEE

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study by Bang, Soo-Mee, Kang, Jin-Hyoung, Hong, Min Hee, Ahn, Jin-Seok, Oh, So Yeon, Baek, Jin Ho, Choi, Yoon Ji, Shin, Seong Hoon, Kim, Young-Joo, Gil, Ha-Yeong, Park, Hyung-Eun, Lee, Juneyoung, Park, Eun-Lyeong

“…This study assessed epidemiologic data and clinical outcomes, including venous thromboembolism (VTE) recurrence and bleeding events, in patients with…”
Get full text

Brainstem astroblastoma with MN1 translocation by Shin, Sun Ah, Ahn, Bokyung, Kim, Seung‐Ki, Kang, Hyoung Jin, Nobusawa, Sumihito, Komori, Takashi, Park, Sung‐Hye

“…Astroblastoma is a rare glial neoplasm that occurs mostly in the cerebral hemisphere of children, adolescents and young adults. Although astroblastic…”
Get full text